2Eschbach JW, Egrie J, Down MR, et al. Correction of the anemia of end stage renal disease with recombinant human erythropioetin,result of a combined phase and clinical trial[J].New Engl J Med, 1987,316(1) : 73-78.
3Vaziri ND. Mechanism of erythropoietin-indueed hypertension[J]. Am J Kidney Dis,1999.33(5) 1821-828.
4Vaziri ND,Tamai O, Kohno K, et al. Cardiovascular effects of erythropoietin and anemia correction [J]. Curr Opin Nephrol Hyoertens,2001, 10(5) :633-637.
5Parker KP,Mitch WE,Stivelman JC,et al. Safety and efficacy of low dose subcutaneous erythropoietin in hemodialysis patients[J]. J Am Soc Nephrol, 1997,8(5) :288-293.
6Macougall IC,Tucker B,Thompson J,et al.A randomized conreolled study of iron supplementation in patients treated with erythropoietin.Kidney Int,1996,50(5):1694-1699.
7Sloand JA,Shelly MA,Feigin A,et al.A double-blind,placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome.Am J Kidney Dis,2004,43(4):663-670.
8Zyl-Smit R,Halkett JA.Experience with the use of iron polymaltose(Dextrin) complex given by single total dose infusion to stable chronic haemodialysis patients.Nephron,2002,92:316-323.
9Anuradha S,Singh NP,Agarwal SK.Total dose infusion iron dextran therapy in predialysis chronic renal!failure patients.Ren Fail,2002,24(3):307-313.
10EschbachJW,EgrieJC,DowningMR.Correctionoftheanemiaofend-stagerenaldiseasewithrecombinanthumanerythropoietin[].The New England Journal of Medicine.1987
